International Journal of Biological and Biomedical Research

A Comparative Study of mRNA Vaccines and Viral Vector Vaccines in COVID-19

Andrea Rossi
Department of Pharmacology, University of Milan, Italy

* Corresponding Author: **Andrea Rossi**

Article Info

Volume: 01
Issue: 02
March-April 2025
Received: 20-03-2025
Accepted: 12-04-2025
Page No: 06-08

Abstract
The COVID-19 pandemic prompted unprecedented global efforts in vaccine development. Among the prominent platforms, mRNA vaccines (e.g., Pfizer-BioNTech, Moderna) and viral vector vaccines (e.g., AstraZeneca, Johnson & Johnson) were developed at record speed. This article offers a comprehensive comparative analysis of these two technologies, examining their mechanisms, efficacy, safety profiles, storage requirements, global distribution, and public perception. It further expands on immunological responses, policy implications, and lessons for future pandemic preparedness. The article aims to present a scientific yet accessible synthesis of current evidence to inform public health strategies and research priorities.

Keywords: COVID-19, mRNA vaccine, viral vector vaccine, vaccine efficacy, side effects, global distribution, SARS-CoV-2, immunogenicity, vaccine hesitancy, biotechnology, pandemic preparedness, vaccine platforms

1. Introduction

COVID-19, caused by the novel coronavirus SARS-CoV-2, emerged in late 2019 and quickly escalated into a global health crisis. The urgent need for effective vaccines led to the rapid development and deployment of several vaccine types. Among them, two platforms stood out: mRNA vaccines and viral vector vaccines. These technologies, though different in design and implementation, became the frontline defense against the pandemic. This study provides a detailed comparison between mRNA and viral vector vaccines, assessing their scientific foundation, real-world effectiveness, and sociopolitical implications.

2. Mechanism of Action

2.1 mRNA Vaccines

mRNA vaccines, such as Pfizer-BioNTech's BNT162b2 and Moderna's mRNA-1273, use synthetic messenger RNA to instruct cells to produce the spike protein of SARS-CoV-2. This triggers an immune response without exposing the body to the live virus. These vaccines do not alter DNA and degrade naturally after translation.

2.2 Viral Vector Vaccines

Viral vector vaccines, like AstraZeneca's ChAdOx1 nCoV-19 and Johnson & Johnson's Ad26.COV2.S, use a harmless adenovirus to deliver DNA encoding the spike protein. The vector enters cells and uses the host machinery to produce the spike protein, eliciting an immune response.

3. Development and Approval Timelines

Both vaccine types were developed under "Operation Warp Speed" and emergency frameworks. mRNA vaccines reached market first, owing to the rapid manufacturing capabilities. Viral vector vaccines followed, benefiting from previous vector research (e.g., Ebola).

4. Efficacy in Clinical Trials

4.1 mRNA Vaccines

- Pfizer-BioNTech: ~95% efficacy in preventing symptomatic COVID-19
- Moderna: ~94.1% efficacy

4.2 Viral Vector Vaccines

- AstraZeneca: ~70.4% efficacy (varied across trials)
- Johnson & Johnson: ~66.3% efficacy globally, higher against severe illness

5. Real-World Effectiveness

Real-world studies confirmed clinical findings. mRNA vaccines showed high effectiveness against severe illness and hospitalization, even with emerging variants. Viral vector vaccines performed well but showed reduced protection against some variants, such as Beta and Delta.

6. Safety and Side Effects

6.1 mRNA Vaccines

Common: Soreness, fever, fatigue. Rare: Myocarditis (especially in younger males)

6.2 Viral Vector Vaccines

Common: Flu-like symptoms. Rare: Thrombosis with thrombocytopenia syndrome (TTS), particularly with AstraZeneca

7. Storage and Distribution

- mRNA vaccines require ultra-cold storage (-70°C for Pfizer), posing logistical challenges in low-resource areas.
- Viral vector vaccines are more stable at normal refrigeration temperatures (2–8°C), easing distribution in developing countries.

8. Public Perception and Vaccine Hesitancy

mRNA vaccines initially faced skepticism due to their novel mechanism. Over time, transparency and efficacy data increased public trust. Viral vector vaccines were initially more acceptable but faced setbacks due to rare side effects.

9. Global Distribution and Equity

Viral vector vaccines were more accessible to low- and middle-income countries due to ease of storage and cost. mRNA vaccines dominated high-income markets. COVAX and WHO efforts aimed to balance this inequity.

10. Booster Doses and Variant Response

- mRNA platforms were rapidly adapted for boosters targeting Omicron.
- Viral vector vaccines also updated, but with slower rollout.

11. Technological Advancements and Future Potential

mRNA technology proved scalable and adaptable, paving the way for vaccines against other diseases (e.g., influenza, cancer). Viral vectors remain valuable for single-dose efficacy and long-term immunity studies.

12. Immunological Response and Durability

Studies show that mRNA vaccines elicit strong neutralizing antibody responses and robust CD4+/CD8+ T cell activation. Viral vector vaccines also generate broad T cell responses, often with a slower antibody peak. Durability varies by platform, with boosters enhancing long-term protection.

13. Comparative Summary Table

Table 1

Feature	mRNA Vaccines	Viral Vector Vaccines
Mechanism	Delivers mRNA	Uses adenovirus vector
Examples	Pfizer, Moderna	AstraZeneca, J&J
Efficacy	~94–95%	~66–70%
Side Effects	Mild to moderate, rare myocarditis	Mild to moderate, rare blood clots
Storage	Ultra-cold	Refrigerated
Cost	Higher	Lower
Adaptability	Rapid	Moderate
Dosing	2 doses + booster	1 dose + booster (optional)

14. Ethical, Regulatory, and Policy Considerations

Emergency Use Authorizations (EUAs) raised debates on data transparency and regulatory rigor. Ethical questions emerged around vaccine nationalism and intellectual property rights. WHO's call for temporary patent waivers stirred global discourse. Informed consent, equitable allocation, and compensation for adverse effects became key policy pillars.

15. Case Studies: Country-Level Deployment

- **Israel**: Mass mRNA rollout with real-time data monitoring.
- **India**: AstraZeneca's Covishield widely used due to manufacturing ease.
- **USA**: Diverse deployment with both vaccine types.
- **Brazil**: Mixed vaccine strategy combining mRNA and vector vaccines.

16. Lessons for Future Pandemics

- Investment in flexible platforms (like mRNA)
- Importance of transparent communication
- Equitable global supply chains
- Regulatory preparedness
- Infrastructure development for vaccine storage and delivery

17. Conclusion

Both mRNA and viral vector vaccines played vital roles in the fight against COVID-19. Each brought unique strengths and challenges. mRNA vaccines excelled in efficacy and adaptability; viral vector vaccines offered ease of distribution and affordability. A diversified vaccine approach proved essential in curbing the pandemic, and continued research in both domains remains crucial for future global health security.

18. References

1. Polack FP, *et al*. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
2. Baden LR, *et al*. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
3. Voysey M, *et al*. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine. Lancet. 2021;397(10269):99–111.

4. Sadoff J, *et al*. Safety and efficacy of single-dose Ad26.COV2.S vaccine. N Engl J Med. 2021;384(23):2187–2201.
5. World Health Organization. COVAX Initiative Reports. 2021.
6. Centers for Disease Control and Prevention. Vaccine Adverse Event Reporting System (VAERS). 2021.
7. European Medicines Agency. Regulatory Guidelines. 2021.
8. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516–527.
9. Barouch DH. Covid-19 vaccines—immunity, variants, boosters. N Engl J Med. 2022;387(10):887–897.
10. Dagan N, *et al*. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–1423.
11. Ramasamy MN, *et al*. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine. Lancet. 2020;396(10249):1979–1993.
12. Folegatti PM, *et al*. Safety and immunogenicity of a candidate MERS-CoV viral-vectored vaccine. Lancet Infect Dis. 2020;20(7):816–826.
13. Thompson MG, *et al*. Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. N Engl J Med. 2021;385(15):1355–1371.
14. Suthar MS, *et al*. Rapid generation of neutralizing antibody responses. Cell Rep Med. 2020;1(3):100040.
15. Collier DA, *et al*. Impact of SARS-CoV-2 variants on vaccine efficacy. Nat Rev Immunol. 2021;21(8):464–478.
16. Khoury DS, *et al*. Neutralizing antibody levels and protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211.
17. Mahase E. Covid-19: What do we know about the late stage vaccine candidates? BMJ. 2020;371:m4576.
18. Liu X, *et al*. Safety and immunogenicity of heterologous versus homologous prime-boost schedules. Lancet. 2021;398(10303):856–869.
19. Baden LR, *et al*. Durability of mRNA-1273 vaccine. N Engl J Med. 2022;386(9): 884–886.
20. Rosenblum HG, *et al*. Safety of mRNA vaccines—initial post-authorization findings. MMWR Morb Mortal Wkly Rep. 2021;70(24):895–900.
21. Greinacher A, *et al*. Thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(22):2092–2101.
22. Lee GM, *et al*. Covid-19 vaccine safety updates. Pediatrics. 2021;148(6):e2021053744.
23. Painter MM, *et al*. Immune responses after mRNA vaccination. Sci Immunol. 2021;6(58):eabg4054.
24. Ledford H. How mRNA vaccines rose to prominence. Nature. 2021;589(7842):20-22.
25. Sah P, *et al*. Asymptomatic SARS-CoV-2 infection: A systematic review. Proc Natl Acad Sci U S A. 2021;118(34):e2109229118.